Clinical Outcomes of Proton Beam Therapy for Choroidal Melanoma at a Single Institute in Korea
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Purpose This study retrospectively evaluated the clinical outcomes and complications of proton beam therapy (PBT) in a single institution in Korea and quantitatively analyzed the change in tumor volume after PBT using magnetic resonance imaging (MRI). Materials and Methods Twenty-four treatment-naïve patients who underwent PBT for choroidal melanoma between 2009 and 2015 were reviewed. Dose fractionation was 60-70 cobalt gray equivalents over 5 fractions. Orbital MRIs were taken at baseline and 3, 6, and 12 months after PBT and annually thereafter. The tumor volume was reconstructed and evaluated by stacking the tumor boundary in each thin-sliced axial T1-weighted image using MIM software. Results The median follow-up duration was 36.5 months (range, 9 to 82 months). One patient had suspicious local progression and two patients had distant metastasis. The 3-year local progression- free survival, distant metastasis-free survival, and overall survival rates were 95.8%, 95.8%, and 100%, respectively. Five Common Terminology Criteria for Adverse Event ver. 4.03 grade 3-4 toxicities were observed in four patients (16.7%), including one with neovascular glaucoma. The mean tumor volume at the baseline MRI was 0.565±0.084 mL (range, 0.074 to 1.610 mL), and the ratios of the mean volume at 3, 6, and 12 months to that at baseline were 81.8%, 67.3%, and 60.4%, respectively. Conclusion The local control rate and complication profile after PBT in patients with choroidal melanoma in Korea were comparable with those reported in a previous PBT series. The change in tumor volume after PBT exhibited a gradual regression pattern on MRI.
Abstract
Purpose This study retrospectively evaluated the clinical outcomes and complications of proton beam therapy (PBT) in a single institution in Korea and quantitatively analyzed the change in tumor volume after PBT using magnetic resonance imaging (MRI). Materials and Methods Twenty-four treatment-naïve patients who underwent PBT for choroidal melanoma between 2009 and 2015 were reviewed. Dose fractionation was 60-70 cobalt gray equivalents over 5 fractions. Orbital MRIs were taken at baseline and 3, 6, and 12 months after PBT and annually thereafter. The tumor volume was reconstructed and evaluated by stacking the tumor boundary in each thin-sliced axial T1-weighted image using MIM software. Results The median follow-up duration was 36.5 months (range, 9 to 82 months). One patient had suspicious local progression and two patients had distant metastasis. The 3-year local progression- free survival, distant metastasis-free survival, and overall survival rates were 95.8%, 95.8%, and 100%, respectively. Five Common Terminology Criteria for Adverse Event ver. 4.03 grade 3-4 toxicities were observed in four patients (16.7%), including one with neovascular glaucoma. The mean tumor volume at the baseline MRI was 0.565±0.084 mL (range, 0.074 to 1.610 mL), and the ratios of the mean volume at 3, 6, and 12 months to that at baseline were 81.8%, 67.3%, and 60.4%, respectively. Conclusion The local control rate and complication profile after PBT in patients with choroidal melanoma in Korea were comparable with those reported in a previous PBT series. The change in tumor volume after PBT exhibited a gradual regression pattern on MRI.
참고문헌 (37)
- Virgili G, "Incidence of uveal melanoma in Europe", Ophthalmology, 114, pp.2309~2315 (2007)[DOI]
- Singh AD, "Uveal melanoma: trends in incidence, treatment, and survival", Ophthalmology, 118, pp.1881~1885 (2011)[DOI]
- Diener-West M, "Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23", J Clin Oncol, 22, pp.2438~2444 (2004)[DOI]
- Shields JA, "Management of posterior uveal melanoma: past, present, and future: the 2014 Charles L. Schepens lecture", Ophthalmology, 122, pp.414~428 (2015)[DOI]
- Gragoudas ES, "Long-term risk of local failure after proton therapy for choroidal", ciliary body melanoma, 2002, pp.100, 43~48
- Gragoudas E, "Evidence-based estimates of outcome in patients irradiated for intraocular melanoma", Arch Ophthalmol, 120, pp.1665~1671 (2002)[DOI]
- Egger E, "Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma", Int J Radiat Oncol Biol Phys, 51, pp.138~147 (2001)
- Kaneko A, "Malignant ophthalmic tumors", Nihon Rinsho, 51(Suppl), pp.1013~1020 (1993)
- Kuo PK, "Uveal melanoma in China", Int Ophthalmol Clin, 22, pp.57~71 (1982)[DOI]
- Sakamoto T, "Histologic findings and prognosis of uveal malignant melanoma in japanese patients", Am J Ophthalmol, 121, pp.276~283 (1996)[DOI]
- Kwon HJ, "Prognosis of choroidal melanoma and the result of ruthenium brachytherapy combined with transpupillary thermotherapy in Korean patients", Br J Ophthalmol, 97, pp.653~658 (2013)[DOI]
- Shah PK, "Indigenous (125)I brachytherapy source for the management of intraocular melanomas in India", Cancer Biother Radiopharm, 28, pp.21~28 (2013)[DOI]
- Tsuji H, "Carbon-ion radiotherapy for locally advanced or unfavorably located choroidal melanoma: a Phase I", II dose-escalation study, 2007, pp.67, 857~862
- Toyama S, "Long-term results of carbon ion radiation therapy for locally advanced or unfavorably located choroidal melanoma: usefulness of CT-based 2-port orthogonal therapy for reducing the incidence of neovascular glaucoma", Int J Radiat Oncol Biol Phys, 86, pp.270~276 (2013)[DOI]
- Maschi C, "Tumour response in uveal melanomas treated with proton beam therapy", Clin Oncol (R Coll Radiol), 28, pp.198~203 (2016)[DOI]
- Russo A, "Diffusion-weighted magnetic resonance imaging and ultrasound evaluation of choroidal melanomas after proton-beam therapy", Radiol Med, 120, pp.634~640 (2015)[DOI]
- Egan KM, "The risk of enucleation after proton beam irradiation of uveal melanoma", Ophthalmology, 96, pp.1377~1382 (1989)[DOI]
- Gragoudas ES, "Proton beam irradiation of uveal melanomas: the first 30 years. The Weisenfeld Lecture", Invest Ophthalmol Vis Sci, 47, pp.4666~4673 (2006)[DOI]
- Gragoudas ES, "Uveal melanoma: proton beam irradiation", Ophthalmol Clin North Am, 18, pp.111~118 (2005)[DOI]
- Shin D, "Eye tracking and gating system for proton therapy of orbital tumors", Med Phys, 39, pp.4265~4273 (2012)[DOI]
- Jampol LM, "The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19", Ophthalmology, 109, pp.2197~2206 (2002)[DOI]
- Shields JA, "Cobalt plaque therapy of posterior uveal melanomas", Ophthalmology, 89, pp.1201~1207 (1982)[DOI]
- Lommatzsch PK, "Beta-Irradiation of choroidal melanoma with 106Ru", 106Rh applicators. 16 Years' experience, 1983, pp.101, 713~717
- Packer S, "Radiotherapy of choroidal melanoma with iodine-125", Ophthalmology, 87, pp.582~590 (1980)[DOI]
- Gragoudas ES, "The time course of irradiation changes in proton beam-treated uveal melanomas", Ophthalmology, 100, pp.1555~1559 (1993)[DOI]
- Sikuade MJ, "Outcomes of treatment with stereotactic radiosurgery or proton beam therapy for choroidal melanoma", Eye (Lond), 29, pp.1194~1198 (2015)[DOI]
- Mishra KK, "Long-term results of the UCSF-LBNL randomized trial: charged particle with helium ion versus Iodine-125 plaque therapy for choroidal and ciliary body melanoma", Int J Radiat Oncol Biol Phys, 92, pp.376~383 (2015)[DOI]
- Browne AW, "Outcomes of medium choroidal melanomas treated with ruthenium brachytherapy guided by three-dimensional pretreatment modeling", Brachytherapy, 14, pp.718~725 (2015)[DOI]
- Wang Z, "Charged particle radiation therapy for uveal melanoma: a systematic review and meta-analysis", Int J Radiat Oncol Biol Phys, 86, pp.18~26 (2013)[DOI]
- Hocht S, "Proton therapy of uveal melanomas in Berlin: 5 years of experience at the Hahn-Meitner Institute", Strahlenther Onkol, 180, pp.419~424 (2004)[DOI]
- Summanen P, "Radiation related complications after ruthenium plaque radiotherapy of uveal melanoma", Br J Ophthalmol, 80, pp.732~739 (1996)[DOI]
- Foss AJ, "Predictive factors for the development of rubeosis following proton beam radiotherapy for uveal melanoma", Br J Ophthalmol, 81, pp.748~754 (1997)[DOI]
- Suit HD, "Explorotory study of proton radiation therapy using large field techniques and fractionated dose schedules", Cancer, 35, pp.1646~1657 (1975)[DOI]
- Gragoudas ES, "Metastasis from uveal melanoma after proton beam irradiation", Ophthalmology, 95, pp.992~999 (1988)[DOI]
- Bedikian AY, "Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors", Cancer, 76, pp.1665~1670 (1995)[DOI]
- Berry JL, "Outcomes of choroidal melanomas treated with eye physics: a 20-year review", JAMA Ophthalmol, 131, pp.1435~1442 (2013)[DOI]
- Kujala E, "Very long-term prognosis of patients with malignant uveal melanoma", Invest Ophthalmol Vis Sci, 44, pp.4651~4659 (2003)[DOI]